RNAi News
Most Popular RNAi Story
Alnylam cutting third of jobs to devote cash to lead RNAi programs
Alnylam Pharmaceuticals ($ALNY), a developer of RNA-interference (RNAi) drugs, is axing about 33% of its workforce in a restructuring plan that aims to steer the company's dollars into developmental Read more...
Latest Headlines
- January 20, 2012
- October 24, 2011
- May 27, 2011
- March 31, 2011
- March 16, 2011
- February 8, 2011
- February 4, 2011
- January 4, 2011
- November 23, 2010
- November 18, 2010
- June 22, 2010
- January 4, 2010
- December 16, 2009
- November 13, 2009
- September 29, 2009
- July 30, 2009
- June 3, 2009
- May 11, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
